Physician profile
Kepler A Davis
NPI 1740357425
$3,772.76
in general payments reported to CMS, 2019-2025
23 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $343 · 2021: $280 · 2022: $568 · 2023: $850 · 2024: $642 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,715.77 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $684.40 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Gilead Sciences, INC. | $256.75 | 2019-2025 | |
| Octapharma USA, INC. | $145.50 | 2022-2024 | Panzyga |
| Theratechnologies INC. | $134.69 | 2022-2024 | Egrifta, Trogarzo |
| Abbvie INC. | $95.69 | 2023-2025 | Teflaro |
| Insmed, INC. | $93.33 | 2019-2023 | Arikayce |
| Melinta Therapeutics, LLC | $78.37 | 2022-2025 | Kimyrsa, Vabomere, Orbactiv |
| Janssen Biotech, INC. | $71.28 | 2019-2023 | Symtuza |
| La Jolla Pharmaceutical Company | $58.21 | 2022-2025 | Xacduro |
| Astellas Pharma US INC | $55.04 | 2023-2025 | Cresemba |
| Tetraphase Pharmaceuticals, INC. | $50.68 | 2019-2020 | |
| Shionogi INC | $47.18 | 2023-2024 | Fetroja |
| Pharming Healthcare, INC. | $40.86 | 2022-2024 | Ruconest |
| Glaxosmithkline, LLC. | $36.92 | 2025 | Shingrix, Arexvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $35.26 | 2025 | Rebyota |
| Aimmune Therapeutics, INC. | $35.23 | 2024-2025 | Vowst |
| Paratek Pharmaceuticals, INC. | $33.24 | 2021-2024 | Nuzyra |
| Emd Serono, INC. | $31.13 | 2025 | |
| Adma Biomanufacturing LLC | $22.68 | 2022 | |
| Hospira, INC. | $21.59 | 2023 | |
| Allergan, INC. | $14.95 | 2020 | |
| Pfizer INC. | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kepler Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.